1
|
Nasello C, Poppi LA, Wu J, Kowalski TF, Thackray JK, Wang R, Persaud A, Mahboob M, Lin S, Spaseska R, Johnson CK, Gordon D, Tissir F, Heiman GA, Tischfield JA, Bocarsly M, Tischfield MA. Human mutations in high-confidence Tourette disorder genes affect sensorimotor behavior, reward learning, and striatal dopamine in mice. Proc Natl Acad Sci U S A 2024; 121:e2307156121. [PMID: 38683996 PMCID: PMC11087812 DOI: 10.1073/pnas.2307156121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2023] [Accepted: 02/13/2024] [Indexed: 05/02/2024] Open
Abstract
Tourette disorder (TD) is poorly understood, despite affecting 1/160 children. A lack of animal models possessing construct, face, and predictive validity hinders progress in the field. We used CRISPR/Cas9 genome editing to generate mice with mutations orthologous to human de novo variants in two high-confidence Tourette genes, CELSR3 and WWC1. Mice with human mutations in Celsr3 and Wwc1 exhibit cognitive and/or sensorimotor behavioral phenotypes consistent with TD. Sensorimotor gating deficits, as measured by acoustic prepulse inhibition, occur in both male and female Celsr3 TD models. Wwc1 mice show reduced prepulse inhibition only in females. Repetitive motor behaviors, common to Celsr3 mice and more pronounced in females, include vertical rearing and grooming. Sensorimotor gating deficits and rearing are attenuated by aripiprazole, a partial agonist at dopamine type II receptors. Unsupervised machine learning reveals numerous changes to spontaneous motor behavior and less predictable patterns of movement. Continuous fixed-ratio reinforcement shows that Celsr3 TD mice have enhanced motor responding and reward learning. Electrically evoked striatal dopamine release, tested in one model, is greater. Brain development is otherwise grossly normal without signs of striatal interneuron loss. Altogether, mice expressing human mutations in high-confidence TD genes exhibit face and predictive validity. Reduced prepulse inhibition and repetitive motor behaviors are core behavioral phenotypes and are responsive to aripiprazole. Enhanced reward learning and motor responding occur alongside greater evoked dopamine release. Phenotypes can also vary by sex and show stronger affection in females, an unexpected finding considering males are more frequently affected in TD.
Collapse
Affiliation(s)
- Cara Nasello
- Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, Piscataway, NJ08854
- Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ08854
| | - Lauren A. Poppi
- Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, Piscataway, NJ08854
- Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ08854
- Child Health Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ08901
| | - Junbing Wu
- Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ08854
- Child Health Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ08901
| | - Tess F. Kowalski
- Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ08854
- Child Health Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ08901
| | - Joshua K. Thackray
- Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, Piscataway, NJ08854
- Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ08854
| | - Riley Wang
- Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, Piscataway, NJ08854
- Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ08854
| | - Angelina Persaud
- Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ08854
- Child Health Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ08901
| | - Mariam Mahboob
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers New Jersey Medical School and Rutgers Biomedical and Health Sciences, Newark, NJ07103
| | - Sherry Lin
- Department of Neurobiology, Harvard Medical School, Boston, MA02115
| | - Rodna Spaseska
- Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, Piscataway, NJ08854
| | - C. K. Johnson
- Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, Piscataway, NJ08854
| | - Derek Gordon
- Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, Piscataway, NJ08854
| | - Fadel Tissir
- College of Health and Life Sciences, Hamad Bin Khalifa University, Doha34110, Qatar
- Laboratory of Developmental Neurobiology, Institute of Neuroscience, Université Catholique de Louvain, Brussels1200, Belgium
| | - Gary A. Heiman
- Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, Piscataway, NJ08854
| | - Jay A. Tischfield
- Department of Genetics and the Human Genetics Institute of New Jersey, Rutgers University, Piscataway, NJ08854
| | - Miriam Bocarsly
- Department of Pharmacology, Physiology, and Neuroscience, Rutgers New Jersey Medical School and Rutgers Biomedical and Health Sciences, Newark, NJ07103
| | - Max A. Tischfield
- Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ08854
- Child Health Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ08901
| |
Collapse
|
2
|
Zoh RS, Esteves BH, Yu X, Fairchild AJ, Vazquez AI, Chapple AG, Brown AW, George B, Gordon D, Landsittel D, Gadbury GL, Pavela G, de Los Campos G, Mestre LM, Allison DB. Design, analysis, and interpretation of treatment response heterogeneity in personalized nutrition and obesity treatment research. Obes Rev 2023; 24:e13635. [PMID: 37667550 PMCID: PMC10825777 DOI: 10.1111/obr.13635] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2022] [Revised: 03/29/2023] [Accepted: 07/24/2023] [Indexed: 09/06/2023]
Abstract
It is increasingly assumed that there is no one-size-fits-all approach to dietary recommendations for the management and treatment of chronic diseases such as obesity. This phenomenon that not all individuals respond uniformly to a given treatment has become an area of research interest given the rise of personalized and precision medicine. To conduct, interpret, and disseminate this research rigorously and with scientific accuracy, however, requires an understanding of treatment response heterogeneity. Here, we define treatment response heterogeneity as it relates to clinical trials, provide statistical guidance for measuring treatment response heterogeneity, and highlight study designs that can quantify treatment response heterogeneity in nutrition and obesity research. Our goal is to educate nutrition and obesity researchers in how to correctly identify and consider treatment response heterogeneity when analyzing data and interpreting results, leading to rigorous and accurate advancements in the field of personalized medicine.
Collapse
Affiliation(s)
- Roger S Zoh
- Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, Indiana, USA
| | | | - Xiaoxin Yu
- Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, Indiana, USA
| | - Amanda J Fairchild
- Department of Psychology, University of South Carolina, Columbia, South Carolina, USA
| | - Ana I Vazquez
- Department of Epidemiology and Biostatistics, Michigan State University, Lansing, Michigan, USA
| | - Andrew G Chapple
- Biostatistics Program, School of Public Health, LSU Health Sciences Center, New Orleans, Louisiana, USA
| | - Andrew W Brown
- Department of Applied Health Science, Indiana University School of Public Health-Bloomington, Bloomington, Indiana, USA
| | - Brandon George
- College of Population Health, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| | - Derek Gordon
- Department of Genetics, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
| | - Douglas Landsittel
- Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, Indiana, USA
| | - Gary L Gadbury
- Department of Statistics, Kansas State University, Manhattan, Kansa, USA
| | - Greg Pavela
- Department of Health Behavior, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Gustavo de Los Campos
- Departments of Epidemiology & Biostatistics and Statistics & Probability, IQ - Institute for Quantitative Health Science and Engineering, Michigan State University, Lansing, Michigan, USA
| | - Luis M Mestre
- Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA
| | - David B Allison
- Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, Indiana, USA
| |
Collapse
|
3
|
Walsh T, Duff L, Riviere ME, Tariot PN, Doak K, Smith M, Borowsky B, Lopez Lopez C, Arratia PC, Liu F, Scholten I, Gordon D, Arbuckle J, Graf A, Quinn M, Ricart J, Langbaum JB. Outreach, Screening, and Randomization of APOE ε4 Carriers into an Alzheimer's Prevention Trial: A global Perspective from the API Generation Program. J Prev Alzheimers Dis 2023; 10:453-463. [PMID: 37357285 PMCID: PMC10426731 DOI: 10.14283/jpad.2023.27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/17/2023]
Abstract
BACKGROUND Alzheimer's disease (AD) prevention trials require a large outreach and screening funnel to identify cognitively unimpaired adults who meet the study's inclusion criteria, such as certain clinical or demographic criteria, genetic risk factors, and/or biomarker evidence of the disease. OBJECTIVES Describe tactics and strategies to identify and enroll cognitively unimpaired adults with one (heterozygotes [HT]) or two (homozygotes [HM]) copies of the APOE ε4 allele, a genetic risk factor for dementia due to AD, into the Alzheimer's Prevention Initiative (API) Generation Program, the largest and only prevention trials for late onset AD using this enrichment technique. DESIGN AND SETTING The Generation Program was comprised of two global, randomized, double-blind, placebo-controlled, parallel group adaptive design with variable treatment duration clinical trials. Generation Study 1 randomized participants into one of two cohorts: Cohort 1 which evaluated CAD106 vs. placebo or Cohort 2 which evaluated umibecestat vs placebo. Generation Study 2 randomized participants into two doses of umibecestat vs. placebo. The Generation Program was terminated early in 2019, while enrollment was still occurring. PARTICIPANTS Both Generation Study 1 and Generation Study 2 enrolled cognitively unimpaired APOE ε4 HMs aged 60-75; Generation Study 2 also enrolled APOE ε4 HTs ages 60-75 with elevated brain amyloid. METHODS AND MEASUREMENTS Describe results of the centralized and localized outreach, recruitment, screening strategies and tactics as well as characteristics of sites successful at enrolling genetically eligible participants, with a particular focus on APOE ε4 HMs given the 2-3% prevalence of this genotype. RESULTS At the time the trial program was terminated, 35,333 individuals had consented to the optional prescreening ICF1a/ICFA and provided a sample of DNA for APOE genotyping, 1,138 APOE ε4 HMs consented to screening for Generation Study 1 (ICF1b), and 1,626 APOE ε4 carriers were randomized into either Generation Study 1 or Generation Study 2. Genetic testing registries, partnerships with genetic testing/counseling companies, and the optional prescreening ICF1a/ICFA were the most successful strategies for identifying genetically eligible participants for screening. CONCLUSIONS It is feasible to recruit, screen and randomize cognitively unimpaired APOE ε4 carriers, particularly APOE ε4 HMs for a global AD prevention trial. The Generation Program was on track to complete enrollment by end of 2019. Factors that were key to this success included: working with sites to develop customizable outreach, recruitment, and screening programs specific to their site needs, providing forums for sites to exchange best practices, and developing partnerships between the sponsor team and trial sites.
Collapse
Affiliation(s)
- T Walsh
- Jessica Langbaum, PhD, Banner Alzheimer's Institute, 901 E. Willetta Street, Phoenix, AZ 85006, USA,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Amin M, del Bosque-Plata L, Gonzalez MG, Wu R, Postolache TT, Vergate M, Gordon D, Ott J, Gragnoli C. ODP258 CRHR1 gene shows extensive linkage to major depression and type 2 diabetes in Italian families. J Endocr Soc 2022. [PMCID: PMC9629165 DOI: 10.1210/jendso/bvac150.705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Major Depressive Disorder (MDD) and Type 2 Diabetes (T2D) are heterogeneous polygenic and complex disorders and are often comorbid. This shared comorbidity can be partially explained by several genetic, environmental, and hormonal factors such as hypercortisolism in MDD and a subset of patients with T2D. CRH receptor-1 (CRHR1) dysfunction may explain the MDD- and T2D-hypercortisolism, at least in a subgroup of patients. CRHR1-variants predisposing to impaired CRHR1 dosage and/or function may lead to hypercortisolism (substrate for serotonin dysfunction and MDD), as well as hyperglycemia, insulin resistance, and increased visceral fat, all T2D-traits. We hypothesize that CRHR1-variants may impair the stress and cortisol response, conferringincreased risk for MDD, T2D, and MDD-T2D comorbidity. Methods Using 212 Italian families with T2D, enriched T2D-familial history, and MDD, we amplified and tested 158 CRHR1 SNPs by two-point parametric analysis for linkage and linkage-disequilibrium (LD), using the models dominant (D) and recessive (R), with complete (1) and incomplete (2) penetrance (Pseudomarker). Results We detected linkage to and/or LD with MDD: for 93 SNPs (D1), 57 SNPs (D2), 91 SNPs (R1), and 14 (R2); and T2D for 15 SNPs (D1), 18 SNPs (D2), twelve SNPs (R1) and ten SNPs (R2), for a total of 122 SNPs. Specific LD-blocks’ underlined each disorder without overlap. Of note, three independent SNPs were comorbid forMDD and T2D. All risk SNPs are intronic, except for one synonymous, one splice site, one missense, and one 3'UTR. In-silicoanalysis detected functional gene and tridimensional protein changes in a risk-SNP. Conclusion We are the first to report CRHR1 in linkage and LD with MDD and T2D in T2D-families. CRHR1contribution to MDD appears stronger thanthe contribution to T2D and may thus antecede its onset . Genetically impaired stress and cortisol response may lead to comorbid MDD-T2D, likely a molecular-clinical entity in a subset of families. Our findings should be replicated in families from other ethnic groups. Presentation: No date and time listed
Collapse
|
5
|
Lewis TL, Mason L, Gordon D, Ray R. The Clavien-Dindo complication classification modified for foot and ankle orthopaedic surgery. Foot Ankle Surg 2022; 28:800-802. [PMID: 35346593 DOI: 10.1016/j.fas.2022.03.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Accepted: 03/11/2022] [Indexed: 02/04/2023]
Affiliation(s)
- T L Lewis
- King's Foot and Ankle Unit, King's College NHS Foundation Trust, UK
| | - L Mason
- Liverpool University Hospitals NHS Foundation Trust, Liverpool L9 7AL, UK
| | | | - R Ray
- King's Foot and Ankle Unit, King's College NHS Foundation Trust, UK.
| |
Collapse
|
6
|
Morris R, Holtorf S, Paidimukkala N, Schuster T, Monts J, Gordon D. LB807 Evidence for epithelial cells in human and murine blood and bone marrow. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.07.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
McLaughlin CC, Gordon D, Goldhirsh M, McNutt LA. Disentangling the multidimensional aspects of hospital quality and safety surveillance. Ann Epidemiol 2021. [DOI: 10.1016/j.annepidem.2021.05.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Teraoka J, Nguyen K, Hart D, Peace S, Leard L, Iyer G, Gordon D, Zuckerman B, Pascual J, Ponzo J, Perez A, Budanova N, Gesthalter Y, Trinh B, Kukreja J, Hays S, Venado A. Decreasing 30-day Readmissions for Pleural Effusions after Lung Transplant. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.1075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
9
|
Petrov GM, Davidson A, Gordon D, Peñano J. Modeling of short-pulse laser-metal interactions in the warm dense matter regime using the two-temperature model. Phys Rev E 2021; 103:033204. [PMID: 33862825 DOI: 10.1103/physreve.103.033204] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2020] [Accepted: 02/10/2021] [Indexed: 11/07/2022]
Abstract
A numerical model for laser-matter interactions in the warm dense matter regime is presented with broad applications, e.g., ablation, thermionic emission, and radiation. A unique approach is adopted, in which a complete set of collisional and transport data is calculated using a quantum model and incorporated into the classical two-temperature model for the electron and lattice-ion temperatures. The data set was produced by the average atom model that combines speed, conceptual simplicity, and straightforward numerical development. Such data are suitable for use in the warm dense matter regime, where most of the laser-matter interactions at moderate intensities occur, thus eliminating deficiencies of previous models, e.g., interpolation between solid and ideal plasma regimes. In contrast to other works, we use a more rigorous definition of solid and plasma states of the metal, based on the physical condition of the lattice, crystalline (ordered) versus melted (disordered), rather than a definition based on electron temperature. The synergy between the two-temperature and average atom models has been demonstrated on a problem involving heating and melting of the interior of Al by a short-pulse laser with duration 0.1-1 ps and laser fluences 1×10^{3}-3×10^{4}J/m^{2}(0.1-3J/cm^{2}). The melting line, which separates the solid and plasma regimes, has been tracked in time and space. The maximum melting depth has been determined as a function of laser fluence: l_{melt}(μm)≅4×10^{3}F(J/m^{2}).
Collapse
Affiliation(s)
- G M Petrov
- Naval Research Laboratory, Plasma Physics Division, 4555 Overlook Avenue SW, Washington, DC 20375, USA
| | - A Davidson
- Naval Research Laboratory, Plasma Physics Division, 4555 Overlook Avenue SW, Washington, DC 20375, USA
| | - D Gordon
- Naval Research Laboratory, Plasma Physics Division, 4555 Overlook Avenue SW, Washington, DC 20375, USA
| | - J Peñano
- Naval Research Laboratory, Plasma Physics Division, 4555 Overlook Avenue SW, Washington, DC 20375, USA
| |
Collapse
|
10
|
Ginath S, Alcalay M, Ben Ami M, Bssam Abbas Y, Cohen G, Condrea A, Feit H, Gershi H, Gold R, Goldschmidt E, Gordon D, Groutz A, Lavy Y, Levy G, Lowenstein L, Marcus N, Padoa A, Samuelof A, Tevet A, Weintraub AY. The impact of a nationwide hands-on workshop on the diagnostic rates and management of obstetrical anal sphincter Injuries in Israel. Colorectal Dis 2020; 22:1677-1685. [PMID: 32583513 DOI: 10.1111/codi.15220] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/08/2020] [Accepted: 05/14/2020] [Indexed: 02/08/2023]
Abstract
AIM The aim was to evaluate the influence of a half day, hands-on, workshop on the detection and repair of obstetric anal sphincter injuries (OASIs). METHOD Starting in February 2011, hands-on workshops for the diagnosis and repair of OASIs were delivered by trained urogynaecologists in departments of tertiary medical centres in Israel. The structure of the hands-on workshop resembles the workshop organized at the International Urogynecological Association annual conferences. Participants included medical staff, midwives and surgical residents from each medical centre. We collected data regarding the rate of OASIs, 1 year before and 1 year following the workshop, in 11 medical centres. The study population was composed of parturients with the following inclusion criteria: singleton pregnancy, vertex presentation and vaginal delivery. Pre-viable preterm gestations (< 24 weeks), birth weight < 500 g, stillborn, and those with major congenital anomalies, multifoetal pregnancies, breech presentations and caesarean deliveries were excluded from the analysis. RESULTS In the reviewed centres, 70 663 (49.3%) women delivered prior to the workshop (pre-workshop group) and 72 616 (50.7%) women delivered following the workshop (post-workshop group). Third- or fourth-degree perineal tears occurred in 248 women (0.35%) before the workshop, and in 328 (0.45%) following the workshop, a significant increase of 28.7% (P = 0.002). The increase in diagnosis was significant also in women with third-degree tears alone, 226 women (0.32%) before the workshop and 298 (0.41%) following the workshop, an increase of 28.3% (P = 0.005). CONCLUSION The detection rate of OASIs has significantly increased following the hands-on workshop. The implementation of such programmes is crucial for increasing awareness and detection rates of OASI following vaginal deliveries.
Collapse
Affiliation(s)
- S Ginath
- Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - M Alcalay
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Ramat Gan, Israel
| | - M Ben Ami
- Department of Obstetrics and Gynecology, Baruch Padeh Medical Center, Poriya, Israel.,Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Ramat Gan, Israel
| | - Y Bssam Abbas
- Department of Obstetrics and Gynecology, Baruch Padeh Medical Center, Poriya, Israel.,Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Ramat Gan, Israel
| | - G Cohen
- Department of Obstetrics and Gynecology, Bnei Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - A Condrea
- Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - H Feit
- Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel.,Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - H Gershi
- Department of Obstetrics and Gynecology, Mayanei HaYeshua Medical Center, Bnei Brak, Israel
| | - R Gold
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Obstetrics and Gynecology, Tel Aviv Sourasky Medical Center, Lis Maternity Hospital, Tel Aviv, Israel
| | - E Goldschmidt
- Department of Obstetrics and Gynecology, Bnei Zion Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - D Gordon
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Obstetrics and Gynecology, Tel Aviv Sourasky Medical Center, Lis Maternity Hospital, Tel Aviv, Israel
| | - A Groutz
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Obstetrics and Gynecology, Tel Aviv Sourasky Medical Center, Lis Maternity Hospital, Tel Aviv, Israel
| | - Y Lavy
- Department of Obstetrics and Gynecology, Hadassah Mount Scopus, Jerusalem, Israel.,Hebrew University, Jerusalem, Israel
| | - G Levy
- Department of Obstetrics and Gynecology, Mayanei HaYeshua Medical Center, Bnei Brak, Israel
| | - L Lowenstein
- Department of Obstetrics and Gynecology, Rambam Health Care Campus, Haifa, Israel.,Rappaport Faculty of Medicine, Technion, Haifa, Israel
| | - N Marcus
- Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Ramat Gan, Israel.,Department of Obstetrics and Gynecology, Rivka Ziv Medical Center, Safed, Israel
| | - A Padoa
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Department of Obstetrics and Gynecology, Yitzhak Shamir Medical Center, Tsrifin, Israel
| | - A Samuelof
- Hebrew University, Jerusalem, Israel.,Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel
| | - A Tevet
- Hebrew University, Jerusalem, Israel.,Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel
| | - A Y Weintraub
- Department of Obstetrics and Gynecology, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
| |
Collapse
|
11
|
Wong P, Banville J, Wexler R, Priestley E, Marinier A, Bouvier M, Gordon D, Yang J. Favorable therapeutic index of an orally-active small-molecule antagonist of the platelet protease-activated receptor-4, BMS-986141, compared with the P2Y12 antagonist ticagrelor in cynomolgus monkeys. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
BMS-986141 is an orally-active small-molecule platelet thrombin receptor antagonist selective for the protease-activated receptor-4 (PAR4), a human platelet thrombin receptor.
Purpose
This study assessed effects of BMS-986141 vs. the P2Y12 antagonist ticagrelor, a standard of care antiplatelet agent, on arterial thrombosis (AT), mesenteric bleeding time (MBT) and platelet aggregation in monkeys.
Methods
Studies were conducted in models of electrically-mediated carotid artery thrombosis and MBT in anesthetized monkeys. Monkeys were given a single oral dose of BMS-986141 (0.05, 0.1, 0.5 mg/kg) or vehicle (n=8/group). At 2 hr post-dose, in vivo AT, MBT as well as ex vivo platelet aggregation were monitored in the same animal. Ticagrelor was studied as a comparator and given as IV bolus plus infusion at 0.0023+0.017 to 0.075+0.6 (mg/kg+mg/kg/h) (n=5–6/group). Thrombus weight reduction, MBT increase over vehicle, and platelet aggregation inhibition were determined. Peak platelet aggregation responses to activation peptides selective for PAR4 (PAR4-AP, 12.5 μM) and PAR1 (PAR1-AP, 18 μM), to collagen (5 μg/ml) and to ADP (20 μM) were determined by whole blood aggregometry.
Results
BMS-986141 inhibited platelet aggregation induced by PAR4-AP in human and monkey blood in vitro with comparable IC50 of 1.8±0.3 and 1.2±0.3 nM, respectively. BMS-986141 at 0.5 mg/kg completely inhibited platelet aggregation induced by PAR4-AP but not PAR1-AP, ADP and collagen, suggesting PAR4 receptor selectivity. In the AT model, BMS-986141 at 0.05, 0.1 and 0.5 mg/kg reduced thrombus weight by 36±7*, 63±8*, and 88±3%*, respectively (*P<0.05 vs. vehicle). BMS-986141 increased MBT by up to 1.2-fold. In a separate study, ticagrelor at 0.0023+0.017, 0.0068+0.055, 0.0255+0.18 and 0.075+0.6 (mg/kg+mg/kg/h IV) reduced thrombus weight by 19±8, 36±5*, 76±6* and 89±1%*, and increased MBT by respectively by 1.7-, 6.4-*, >10-*, and >10-fold*, respectively (*P<0.05 vs. vehicle).
Conclusion
Comparable antithrombotic efficacy was observed between BMS-986141 and ticagrelor in monkeys. BMS-986141 exhibited lower MBT compared with ticagrelor at equivalent antithrombotic doses. This study suggests that PAR4 antagonism provides a potentially safer antiplatelet therapy.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Research was supported by Bristol-Myers Squibb
Collapse
Affiliation(s)
- P Wong
- Bristol Myers Squibb, Princeton, United States of America
| | - J Banville
- Universite de Montreal, Institute for Research in Immunology and Cancer, Montreal, Canada
| | - R Wexler
- Bristol Myers Squibb, Princeton, United States of America
| | - E Priestley
- Bristol Myers Squibb, Princeton, United States of America
| | - A Marinier
- Universite de Montreal, Institute for Research in Immunology and Cancer, Montreal, Canada
| | - M Bouvier
- Universite de Montreal, Institute for Research in Immunology and Cancer, Montreal, Canada
| | - D Gordon
- Bristol Myers Squibb, Princeton, United States of America
| | - J Yang
- Bristol Myers Squibb, Princeton, United States of America
| |
Collapse
|
12
|
Widom CS, Miller D, Li X, Gordon D, Brzustowicz L. Childhood maltreatment, serotonin transporter gene, and risk for callous and unemotional traits: A prospective investigation. Psychiatry Res 2020; 291:113271. [PMID: 32629297 PMCID: PMC7484357 DOI: 10.1016/j.psychres.2020.113271] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 06/23/2020] [Accepted: 07/01/2020] [Indexed: 11/29/2022]
Abstract
Previous studies have reported associations between the serotonin transporter 5-HTTLPR genotype and antisocial and aggressive traits and between child maltreatment and antisocial traits. However, few studies have examined whether 5-HTTLPR moderates the influence of childhood maltreatment on callous and unemotional traits, a hallmark of psychopathy. Using a prospective cohort design, children with documented cases of maltreatment and matched controls were followed up and interviewed in adulthood. DNA was extracted from blood and saliva (N = 414) and callous-unemotional (CU) traits were assessed. Childhood maltreatment predicted higher CU scores in adulthood, whereas the effect of 5-HTTLPR was not significant. The effect of child maltreatment on CU traits did not differ by genetic risk (high or low activity 5-HTTLPR), whereas controls with the LL genotype had higher CU scores than controls with the SS genotype. Similar results were found for females and White, non-Hispanics, but not for males and Blacks. Variations in 5-HTTLPR did not affect the impact of child maltreatment on CU traits in adulthood. Genetic risk had a stronger effect on adults with lower environmental risk (controls). Having a history of child maltreatment or the LL genotype placed participants at risk for higher levels of callous and unemotional trait scores.
Collapse
Affiliation(s)
- Cathy Spatz Widom
- Psychology Department, John Jay College and Graduate Center, City University of New York, 524W. 59th Street, New York, NY 10019, USA.
| | - Dana Miller
- Psychology Department, John Jay College, City University of New York, 524W. 59th Street, New York, NY 10019, USA
| | - Xuechen Li
- Psychology Department, John Jay College, City University of New York, 524W. 59th Street, New York, NY 10019, USA
| | - Derek Gordon
- Department of Genetics and Human Genetics Institute, Rutgers, The State University of New Jersey, 145 Bevier Road, Piscataway, NJ, 08854-8082, USA
| | - Linda Brzustowicz
- Department of Genetics and Human Genetics Institute, Rutgers, The State University of New Jersey, 145 Bevier Road, Piscataway, NJ, 08854-8082, USA
| |
Collapse
|
13
|
Schnyder J, Monahan J, Smith W, Hope H, Kelly D, Burt D, Huff E, Kaul A, Hildebrand A, Burnette B, Klug N, Bangs M, Gordon D. SAT0143 A PHASE 1 STUDY IN HEALTHY VOLUNTEERS EXPLORING THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-450: A NOVEL ORAL MK2 INHIBITOR. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5645] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:ATI-450, is an investigational small molecule inhibitor of the MAPK-activated protein kinase 2 (MK2) signaling pathway. This pathway drives the expression of multiple cytokines including TNFα, IL-1α and β, and IL-6.Objectives:We evaluated the safety and tolerability of ATI-450 in healthy volunteers as well as pharmacokinetics (PK) and pharmacodynamics (PD). Here we present data from single and multiple ascending dose cohorts. The aim was to select a dose for evaluation in phase 2 in patients with rheumatoid arthritis.Methods:Safety, PK and PD were assessed in a randomized, observer-blind, placebo-controlled, phase 1 study in male and female healthy subjects aged 18-55 (n=77).Part A: Single Ascending Dose (SAD) (n=32, 8 subjects per dose cohort - 2 placebo, 6 active). A single dose of 10mg, 30mg, 50mg and 100mg was tested.Part B: Multiple Ascending Dose (MAD) (n=30, 10 subjects per dose cohort - 2 placebo, 8 active). 10mg BID, 30mg BID and 50mg BID doses were tested over 7 days of administration.Safety and tolerability of ATI-450 was evaluated based on adverse events, clinical laboratory, vital signs, 12-lead ECG, Holter monitoring, and physical examination. Blood was drawn for PK analysis at 0.5, 1, 2, 4, 6, 8, 12 hours, 24, 36, and 48 hours post dose in the SAD cohort and on day 7 of the MAD cohort. PD of ATI-450 were explored by investigating the inhibition of a target biomarker, phospho-HSP27 (pHSP27) and proinflammatory cytokines, TNFα, IL1β, IL6 and IL8 inex-vivoLPS-stimulated blood samples collected 4 and 12 hours post dose on day 7 from subjects in the MAD cohorts.Results:ATI-450 was generally well tolerated. No serious adverse events or severe adverse events were reported, and no adverse events led to discontinuation of the study medication. The most common adverse events (reported by 2 or more subjects who received ATI-450) observed during the trial were dizziness, headache, upper respiratory tract infection, constipation, nausea, and abdominal pain. All adverse events were mild. A trend of a decrease in absolute neutrophil count (ANC) was observed without correlated clinical sequelae.ATI-450 had dose proportional PK with a terminal half-life (t½) of 9-12 hours in the MAD cohort on day 7. A dose and concentration dependent inhibition ofex vivostimulated cytokines and target biomarker was observed. On day 7, patients in the 50mg BID dose (the dose with the highest degree of inhibition) recorded mean trough drug levels (12 hours post dose) that were 1.4, 2.5, 2.5 and 2.4 times greater than the IC80for TNFα, IL1β, IL8 and pHSP27 respectively. Mean Cmax drug levels (4 hours post dose) were 3.6, 6.4, 6.2 and 6.0 times greater than the IC80for TNFα, IL1β, IL8 and pHSP27 respectively. IL6 levels were inhibited by more than 50% for part of the dosing interval.Conclusion:Oral ATI-450 was generally well tolerated at all doses with dose proportional PK. The t½ suggests that once or twice daily oral dosing may be possible. At the 50mg BID dose, marked inhibition of TNFα, IL1β and IL8, IL6 and pHSP27 was observed. ATI-450 has the potential to be an oral, small molecule drug which can target multiple cytokines. Exploration of its benefit to risk profile in patients with rheumatoid arthritis is warranted.Disclosure of Interests:Judy Schnyder Shareholder of: aclaris therapeutics, Employee of: aclaris therapeutics, Joe Monahan Shareholder of: aclaris therapeutics, Employee of: aclaris therapeutics, Walter Smith Shareholder of: aclaris therapeutics, Employee of: aclaris therapeutics, Heidi Hope Shareholder of: aclaris therapeutics, Employee of: aclaris therapeutics, Deborah Kelly Shareholder of: aclaris therapeutics, Employee of: aclaris therapeutics, David Burt Shareholder of: aclaris therapeutics, Employee of: aclaris therapeutics, E Huff Shareholder of: aclaris therapeutics, Employee of: aclaris therapeutics, A Kaul Shareholder of: aclaris therapeutics, Employee of: aclaris therapeutics, A Hildebrand Shareholder of: aclaris therapeutics, Employee of: aclaris therapeutics, B Burnette Shareholder of: aclaris therapeutics, Employee of: aclaris therapeutics, N Klug Shareholder of: aclaris therapeutics, Employee of: aclaris therapeutics, M Bangs Shareholder of: Aclaris Therapeutics, Employee of: Aclaris Therapeutics, David Gordon Shareholder of: aclaris therapeutics, Employee of: aclaris therapeutics
Collapse
|
14
|
Ayoola A, Sukumaran S, Jain K, Kumar R, Gordon D, Honda-Okubo Y, Quinn S, Roy A, Vatandoust S, Koczwara B, Kichenadasse G, Richards A, Mead K, Karapetis C. Efficacy of influenza vaccine (Fluvax) in cancer patients on treatment: a prospective single arm, open-label study. Support Care Cancer 2020; 28:5411-5417. [PMID: 32144585 DOI: 10.1007/s00520-020-05384-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Accepted: 02/26/2020] [Indexed: 11/27/2022]
Abstract
PURPOSE Influenza virus infection has significant morbidity and mortality in patients with medical co-morbidities who are also immunosuppressed. The efficacy of the seasonal influenza vaccine has not been well studied in patients receiving chemotherapy. We assessed the efficacy of seasonal influenza vaccine in patients with non-haematological malignancy on active treatment (chemotherapy and targeted therapy). METHODS A prospective single arm, open label study with 53 patients with non-haematological cancers recruited during the 2011 and 2012 influenza seasons. Participants had one dose of 2011/2012 trivalent vaccine containing strains A/California/7/2009(H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 (Fluvax) prior to or in-between treatment cycles. Haemagglutination inhibition antibody (HIA) titres in serum were measured at baseline 3, 6 and 24 weeks. Primary endpoint: seroconversion rate (SCR) at 3 weeks. Secondary endpoints: late SCR at 6 weeks. rate of sustained sero-protection titres (SPR) at 24 weeks. Seroconversion was defined as postvaccination ≥ 4-fold increase in HIA titre and sero-protection defined as a HIA ≥ 1:40. RESULTS The SCR at 3 weeks were 35%, 30% and 22.5% to the H1N1, H3N2 and B/Bris strains, respectively. There were no new cases of late SC at 6 weeks or 24 weeks. The SPR at 3 weeks were 72.5%, 65% and 40%, respectively, to H1N1, H3N2 and B/Bris. The SPR at 24 weeks to H1N1, H3N2 and B/Bris were 40%, 52.5% and 17.5%, respectively. CONCLUSIONS Patients on various solid tumour treatments achieve sero-protection rate congruent with the general population. The sero-protection HIA titres were not sustained at 24 weeks postvaccination.
Collapse
Affiliation(s)
- A Ayoola
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia.
| | - S Sukumaran
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, 5042, Australia
| | - K Jain
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
| | - R Kumar
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
| | - D Gordon
- Department of Microbiology and Infectious Diseases, Flinders University and Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
| | - Y Honda-Okubo
- Department of Endocrinology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
| | - S Quinn
- Department of Statistics, Data Science and Epidemiology, Swinburne University of Technology, Melbourne, 3122, Australia
| | - A Roy
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, 5042, Australia
| | - S Vatandoust
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, 5042, Australia
| | - B Koczwara
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, 5042, Australia
| | - G Kichenadasse
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, 5042, Australia
| | - A Richards
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
| | - K Mead
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
| | - C Karapetis
- Department of Medical Oncology, Flinders Medical Centre, Bedford Park, Adelaide, 5042, Australia
- Flinders Centre for Innovation in Cancer, Flinders University, Bedford Park, Adelaide, 5042, Australia
| |
Collapse
|
15
|
Harland BF, Oberleas D, Ellis R, Gelroth J, Gordon D, Phillips K, Ranhotra G, Shah BG, Stoecker B, Trick KD, Zymonas J. Anion-Exchange Method for Determination of Phytate in Foods: Collaborative Study. J AOAC Int 2020. [DOI: 10.1093/jaoac/69.4.667] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Phytate, a naturally occurring organic compound found in plant seeds, roots, and tubers, was determined in a collaborative study using a modified anion-exchange method. Seven samples (peanut flour, oats, rice, isolated soybean protein, a vegetarian diet composite, wheat bran, and whole wheat bread), supplied as blind duplicate samples, were analyzed in triplicate by 7 collaborators. Phytate concentrations in the samples ranged from 2.38 to 46.70 mg/g. Relative standard deviations (RSD = CV) for repeatability ranged from 2.5 to 10.1%, and for reproducibility, from 4.5 to 11.0%. The method has been adopted official first action.
Collapse
Affiliation(s)
| | - Donald Oberleas
- Howard University, School of Human Ecology, Washington, DC 20059
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Murray L, Mugwagwa A, Horsfall M, Tam P, Teh J, Gordon D, Bennetts J, Joseph M. 504 Infective Endocarditis at a Tertiary Hospital in Adelaide, Australia. Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Affiliation(s)
- P. Swain
- Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK
| | - J. Biggins
- Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK
| | - D. Gordon
- Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK
| |
Collapse
|
18
|
Park H, Lad S, Boland K, Johnson K, Readio N, Jin G, sfaha SA, Patterson KS, Singh A, Yang X, Londono D, Singh A, Trempus C, Gordon D, Wang TC, Morris RJ. Abstract LB-039: Chronic inflammation-mediated contribution of bone marrow-derived epithelial cells and hair follicle stem cells to development of cutaneous neoplasms. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-lb-039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Bone marrow-derived epithelial cells (BMDECs) are recruited to sites of chronic inflammation; however, their clinical significance has not been determined. Here, we used gender-mismatched allogeneic bone marrow transplantation (BMT) in the context of the classical multistage model for murine cutaneous carcinogenesis to probe the recruitment of BMDECs in skin tumors initiated with the carcinogen, dimethylbenz[a]anthracene (DMBA), and promoted with the phorbol ester, 12-O-tetradecanolyphorbol-13-acetate (TPA). We detected clusters of bone marrow-derived cells (BMDCs) in over 40% of papillomas, where they occupied 25% or more of the epithelial lesional area. In the dysplastic ulcers which arose in some irradiated DMBA/TPA treated mice, the magnitude of the recruitment was greater. The BMDCs clustered in the cutaneous epithelium where they became immunoreactive to epidermal keratins, and proliferated and stratified, thereby contributing to the lesions comparably with the progeny of hair follicle stem cells in engrafted Krt1-15Cre;R26R mice. Moreover, cytokeratins were detected by immunostaining and Q-PCR in plastic adherent bone marrow cells (BMCs) cultured in the presence of filter-separated epidermal keratinocytes (KCs). Cytokeratin production was enhanced by bone morphogenetic protein 5 (BMP5). Moreover, BMCs migrated towards the alarmin protein, High Mobility Group Box 1 (HMGB1), as well as towards epidermal KCs in ex vivo invasion assays. Furthermore, when naïve female mice received BMTs from donors previously treated with DMBA, several papillomas and a squamous cell carcinoma were observed after TPA promotion alone.
We conclude that surprisingly large numbers of BMDECs are recruited to a subset of cutaneous papillomas and dysplastic ulcers and reflect a previously unrecognized systemic contribution to these lesions. We also conclude that carcinogen-exposed cells originating in the BMCs are sufficient to initiate a subset of benign and malignant lesions upon tumor promotion. Ultimately, these findings may provide novel targets for treatment of non-melanoma skin cancers as well as other cancers.
Citation Format: Heuijoon Park, Sonali Lad, Kelsey Boland, Kelly Johnson, Nyssa Readio, Guangchun Jin, Samuel A sfaha, Kelly S. Patterson, Ashok Singh, Xiangdong Yang, Douglas Londono, Anupama Singh, Carol Trempus, Derek Gordon, Timothy C. Wang, Rebecca J. Morris. Chronic inflammation-mediated contribution of bone marrow-derived epithelial cells and hair follicle stem cells to development of cutaneous neoplasms [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-039.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | - Carol Trempus
- 4National Institute of Environmental Health Sciences, Research Triangle Park, NC
| | | | | | | |
Collapse
|
19
|
Behrendt R, Hocking Edwards JE, Gordon D, Hyder M, Kelly M, Cameron F, Byron J, Raeside M, Kearney G, Thompson AN. Offering maternal composite ewes higher levels of nutrition from mid-pregnancy to lambing results in predictable increases in birthweight, survival and weaning weight of their lambs. Anim Prod Sci 2019. [DOI: 10.1071/an18505] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Management of nutrition during pregnancy for maternal composite ewes has the potential to improve lamb production and survival in prime lamb production systems but existing condition score (CS) guidelines developed for Merinos may not be appropriate for the optimum production of maternal ewes. To address this, three replicated experiments were conducted at two research sites in Victoria and one in Western Australia. Ewes (781–800 per site) were allocated to four CS treatments following pregnancy scanning (~Day 50) and differentially fed to reach approximate targets of CS 2.4, 2.8, 3.2 and 3.6 by lambing. Single and multiple bearing ewes grazed together, and nutritional treatments were applied until the end of lambing after which ewes and lambs were aggregated into management groups containing all treatments. At lambing, maternal ewe liveweight had a range between treatments of 13.7–19.1 kg (average 16.4 kg) and CS varied by 1.1–1.5 of a CS (average 1.24). Across site analysis indicated that lamb birthweight and weaning weight increased with application of higher CS treatments (P < 0.001). There was also an improvement in survival of multiple born lambs with increasing CS at lambing (P < 0.001). Birthweight was significantly related to survival (P < 0.001) at all sites with no significant effect of birth type on lamb survival. Changes in birthweight and weaning weight could be predicted from ewe joining liveweight, ewe liveweight change to Day 90 and ewe liveweight change Day 90 to lambing. The coefficients derived for each of these effects were similar to those found in previous experiments examining Merino and crossbred Border Leicester Merino ewes. The optimum CS targets for multiple bearing maternal composite ewes may be higher than the industry recommended target for Merino ewes based on advantages in lamb survival and weaning weight.
Collapse
|
20
|
Park H, Lad S, Boland K, Johnson K, Readio N, Jin G, Asfaha S, Patterson KS, Singh A, Yang X, Londono D, Singh A, Trempus C, Gordon D, Wang TC, Morris RJ. Bone marrow-derived epithelial cells and hair follicle stem cells contribute to development of chronic cutaneous neoplasms. Nat Commun 2018; 9:5293. [PMID: 30546048 PMCID: PMC6294255 DOI: 10.1038/s41467-018-07688-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2014] [Accepted: 11/09/2018] [Indexed: 12/17/2022] Open
Abstract
We used allogeneic bone marrow transplantation (BMT) and a mouse multistage cutaneous carcinogenesis model to probe recruitment of bone marrow-derived epithelial cells (BMDECs) in skin tumors initiated with the carcinogen, dimethylbenz[a]anthracene (DMBA), and promoted with 12-O-tetradecanolyphorbol-13-acetate (TPA). BMDECs clustered in the lesional epithelium, expressed cytokeratins, proliferated, and stratified. We detected cytokeratin induction in plastic-adherent bone marrow cells (BMCs) cultured in the presence of filter-separated keratinocytes (KCs) and bone morphogenetic protein 5 (BMP5). Lineage-depleted BMCs migrated towards High Mobility Group Box 1 (HMGB1) protein and epidermal KCs in ex vivo invasion assays. Naive female mice receiving BMTs from DMBA-treated donors developed benign and malignant lesions after TPA promotion alone. We conclude that BMDECs contribute to the development of papillomas and dysplasia, demonstrating a systemic contribution to these lesions. Furthermore, carcinogen-exposed BMCs can initiate benign and malignant lesions upon tumor promotion. Ultimately, these findings may suggest targets for treatment of non-melanoma skin cancers.
Collapse
Affiliation(s)
- Heuijoon Park
- Department of Pathology and Cell Biology, Columbia University, New York, 10032, NY, USA
- Department of Dermatology, Columbia University, New York, 10032, NY, USA
- Division of Digestive and Liver Diseases, Department of Medicine and Irving Cancer Center, Columbia University, New York, 10032, NY, USA
- The Hormel Institute, University of Minnesota, Austin, 55912, MN, USA
| | - Sonali Lad
- The Hormel Institute, University of Minnesota, Austin, 55912, MN, USA
| | - Kelsey Boland
- The Hormel Institute, University of Minnesota, Austin, 55912, MN, USA
| | - Kelly Johnson
- The Hormel Institute, University of Minnesota, Austin, 55912, MN, USA
| | - Nyssa Readio
- The Hormel Institute, University of Minnesota, Austin, 55912, MN, USA
| | - Guangchun Jin
- Division of Digestive and Liver Diseases, Department of Medicine and Irving Cancer Center, Columbia University, New York, 10032, NY, USA
| | - Samuel Asfaha
- Division of Digestive and Liver Diseases, Department of Medicine and Irving Cancer Center, Columbia University, New York, 10032, NY, USA
| | - Kelly S Patterson
- Division of Digestive and Liver Diseases, Department of Medicine and Irving Cancer Center, Columbia University, New York, 10032, NY, USA
| | - Ashok Singh
- The Hormel Institute, University of Minnesota, Austin, 55912, MN, USA
| | - Xiangdong Yang
- Division of Digestive and Liver Diseases, Department of Medicine and Irving Cancer Center, Columbia University, New York, 10032, NY, USA
| | - Douglas Londono
- Department of Genetics, Rutgers, The State University of New Jersey, Piscataway, 08854-8082, NJ, USA
| | - Anupama Singh
- The Hormel Institute, University of Minnesota, Austin, 55912, MN, USA
| | - Carol Trempus
- Matrix Biology Group, Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, 27709, NC, USA
| | - Derek Gordon
- Department of Genetics, Rutgers, The State University of New Jersey, Piscataway, 08854-8082, NJ, USA
| | - Timothy C Wang
- Division of Digestive and Liver Diseases, Department of Medicine and Irving Cancer Center, Columbia University, New York, 10032, NY, USA
| | - Rebecca J Morris
- Department of Pathology and Cell Biology, Columbia University, New York, 10032, NY, USA.
- Department of Dermatology, Columbia University, New York, 10032, NY, USA.
- The Hormel Institute, University of Minnesota, Austin, 55912, MN, USA.
| |
Collapse
|
21
|
O’Brien D, Schoenian S, Semler J, Gordon D, Bennett M. 40 Relationship among gastrointestinal nematode infection indicators in meat goat kids. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- D O’Brien
- Virginia State University,Petersburg, United States
| | - S Schoenian
- University of Maryland Extension,Keedysville, MD, United States
| | - J Semler
- University of Maryland Extension,Boonsboro, MD, United States
| | - D Gordon
- University of Maryland Extension,Derwood, MD, United States
| | - M Bennett
- West Virginia University Extension Service,Martinsburg, VA, United States
| |
Collapse
|
22
|
Schoenian S, O’Brien D, Semler J, Gordon D, Bennett M. 409 Eleven Years of the Western Maryland Pasture-Based Meat Goat Performance Test. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- S Schoenian
- University of Maryland Extension,Keedysville, MD, United States
| | - D O’Brien
- Virginia State University,Petersburg, VA, United States
| | - J Semler
- University of Maryland Extension,Boonsboro, MD, United States
| | - D Gordon
- University of Maryland Extension,Derwood, MD, United States
| | - M Bennett
- West Virginia University Extension Service,Martinsburg, VA, United States
| |
Collapse
|
23
|
O’Brien D, Schoenian S, Semler J, Gordon D, Bennett M. PSVI-19 Consistency of FAMACHA© scores to fecal egg counts and gain in meat goat kids. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.1005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- D O’Brien
- Virginia State University,Petersburg, VA, United States
| | - S Schoenian
- University of Maryland Extension,Keedysville, MD, United States
| | - J Semler
- University of Maryland Extension,Boonsboro, MD, United States
| | - D Gordon
- University of Maryland Extension,Derwood, MD, United States
| | - M Bennett
- West Virginia University Extension Service,Martinsburg, WV, United States
| |
Collapse
|
24
|
Haridy J, Wigg A, Muller K, Ramachandran J, Tilley E, Waddell V, Gordon D, Shaw D, Huynh D, Stewart J, Nelson R, Warner M, Boyd M, Chinnaratha MA, Harding D, Ralton L, Colman A, Liew D, Iyngkaran G, Tse E. Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience. J Viral Hepat 2018; 25:1287-1297. [PMID: 29888827 DOI: 10.1111/jvh.12943] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 04/30/2018] [Indexed: 02/06/2023]
Abstract
In March 2016, the Australian government offered unrestricted access to direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) to the entire population. This included prescription by any medical practitioner in consultation with specialists until sufficient experience was attained. We sought to determine the outcomes and experience over the first twelve months for the entire state of South Australia. We performed a prospective, observational study following outcomes of all treatments associated with the state's four main tertiary centres. A total of 1909 subjects initiating DAA therapy were included, representing an estimated 90% of all treatments in the state. Overall, SVR12 was 80.4% in all subjects intended for treatment and 95.7% in those completing treatment and follow-up. 14.2% were lost to follow-up (LTFU) and did not complete SVR12 testing. LTFU was independently associated with community treatment via remote consultation (OR 1.50, 95% CI 1.04-2.18, P = .03), prison-based treatment (OR 2.02, 95% CI 1.08-3.79, P = .03) and younger age (OR 0.98, 95% CI 0.97-0.99, P = .05). Of the 1534 subjects completing treatment and follow-up, decreased likelihood of SVR12 was associated with genotype 2 (OR 0.23, 95% CI 0.07-0.74, P = .01) and genotype 3 (OR 0.23, 95% CI 0.12-0.43, P ≤ .01). A significant decrease in treatment initiation was observed over the twelve-month period in conjunction with a shift from hospital to community-based treatment. Our findings support the high responses observed in clinical trials; however, a significant gap exists in SVR12 in our real-world cohort due to LTFU. A declining treatment initiation rate and shift to community-based treatment highlight the need to explore additional strategies to identify, treat and follow-up remaining patients in order to achieve elimination targets.
Collapse
Affiliation(s)
- J Haridy
- University of Melbourne, Parkville, Vic., Australia.,Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, Vic., Australia
| | - A Wigg
- Hepatology and Liver Transplantation Unit, Flinders Medical Centre, Adelaide, SA, Australia
| | - K Muller
- Hepatology and Liver Transplantation Unit, Flinders Medical Centre, Adelaide, SA, Australia
| | - J Ramachandran
- Hepatology and Liver Transplantation Unit, Flinders Medical Centre, Adelaide, SA, Australia
| | - E Tilley
- Hepatology and Liver Transplantation Unit, Flinders Medical Centre, Adelaide, SA, Australia
| | - V Waddell
- Department of Microbiology and Infectious Diseases, Flinders Medical Centre, Adelaide, SA, Australia
| | - D Gordon
- Department of Microbiology and Infectious Diseases, Flinders Medical Centre, Adelaide, SA, Australia.,Flinders University, Bedford Park, SA, Australia
| | - D Shaw
- Department of Infectious Diseases, Royal Adelaide Hospital, Adelaide, SA, Australia.,Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia
| | - D Huynh
- Department of Gastroenterology, The Queen Elizabeth Hospital, Adelaide, SA, Australia
| | - J Stewart
- Department of Gastroenterology, The Queen Elizabeth Hospital, Adelaide, SA, Australia.,Department of Infectious Diseases, The Queen Elizabeth Hospital, Adelaide, SA, Australia
| | - R Nelson
- Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.,Department of Infectious Diseases, The Queen Elizabeth Hospital, Adelaide, SA, Australia
| | - M Warner
- Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.,Department of Infectious Diseases, The Queen Elizabeth Hospital, Adelaide, SA, Australia
| | - M Boyd
- Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.,Department of Infectious Diseases, Lyell-McEwin Hospital, Adelaide, SA, Australia
| | - M A Chinnaratha
- Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, SA, Australia.,Department of Gastroenterology, Lyell-McEwin Hospital, Adelaide, SA, Australia
| | - D Harding
- Department of Gastroenterology, Lyell-McEwin Hospital, Adelaide, SA, Australia
| | - L Ralton
- Department of Infectious Diseases, Lyell-McEwin Hospital, Adelaide, SA, Australia
| | - A Colman
- Department of Gastroenterology, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - D Liew
- Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, Vic., Australia
| | - G Iyngkaran
- Department of Gastroenterology, Royal Melbourne Hospital, Melbourne, Vic., Australia
| | - E Tse
- Department of Gastroenterology, Royal Adelaide Hospital, Adelaide, SA, Australia
| | | |
Collapse
|
25
|
Henry D, Hirsh V, Kubota K, Steinmetz T, Thomas G, Kang JH, Gordon D, Orlov S, Fleishman A, De Oliveira Brandao C. Randomized, double-blind, placebo (P)-controlled phase III non-inferiority study of darbepoetin alfa (D) for anemia in patients (pts) with advanced NSCLC: An ad hoc subgroup analysis of pts with baseline hemoglobin (Hb) ≤10.0 g/dL. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol 2018; 70:1256-1264. [PMID: 29671280 PMCID: PMC6099508 DOI: 10.1002/art.40511] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2017] [Accepted: 03/22/2018] [Indexed: 01/23/2023]
Abstract
OBJECTIVE To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti-double-stranded DNA (anti-dsDNA) positive (≥30 IU/ml) at baseline. METHODS In this phase III, double-blind, placebo-controlled study (BEL112341; ClinicalTrials.gov identifier: NCT01484496), patients with moderate to severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index [SELENA-SLEDAI] score ≥8) were randomized (2:1) to receive weekly subcutaneous (SC) belimumab 200 mg or placebo, plus standard SLE therapy, for 52 weeks. The primary end point was SLE Responder Index 4 (SRI-4) response rate at week 52. Secondary end points were time to severe flare and reduction in corticosteroid dose (weeks 40-52). Safety was assessed throughout. RESULTS Of the 836 patients in the intent-to-treat (ITT) population, 356 were hypocomplementemic and anti-dsDNA positive at baseline (108 in the placebo group and 248 in the SC belimumab 200 mg group). Compared with placebo, the belimumab group contained more SRI-4 responders (47.2% versus 64.6%; P = 0.0014), had a lower incidence of severe flare according to the SELENA-SLEDAI flare index (31.5% versus 14.1%), and had a greater percentage of patients who reduced corticosteroid dosage by ≥25% to ≤7.5 mg/day during weeks 40-52 (11.4% versus 20.7%; P = 0.0844). Adverse events (AEs) were similar between treatment groups. CONCLUSION Our findings indicate that in hypocomplementemic, anti-dsDNA-positive SLE patients, weekly SC belimumab 200 mg significantly improves SRI-4 response, decreases severe flare incidence, and reduces corticosteroid use versus placebo; a trend toward greater benefit compared with the overall ITT population was observed. AEs were consistent with the known safety profile of belimumab.
Collapse
Affiliation(s)
| | - W. Stohl
- University of Southern CaliforniaLos Angeles
| | - A. Schwarting
- University Medical Center of Johannes Gutenberg UniversityMainzGermany
| | - M. Okada
- St. Luke's International UniversityTokyoJapan
| | | | | | - A. E. Hammer
- GlaxoSmithKlineResearch Triangle ParkNorth Carolina
| | - J. Groark
- GlaxoSmithKlineCollegevillePennsylvania
- Present address:
Aclaris TherapeuticsWaynePennsylvania
| | - D. Bass
- GlaxoSmithKlineCollegevillePennsylvania
- Present address:
Aclaris TherapeuticsWaynePennsylvania
| | - N. L. Fox
- GlaxoSmithKlineRockvilleMaryland
- Present address:
IndiviorRichmondVirginia
| | - D. Roth
- GlaxoSmithKlineCollegevillePennsylvania
- Present address:
Aclaris TherapeuticsWaynePennsylvania
| | - D. Gordon
- GlaxoSmithKlineCollegevillePennsylvania
- Present address:
Aclaris TherapeuticsWaynePennsylvania
| |
Collapse
|
27
|
Lad S, Johnson K, Boland K, Readio N, Schuster T, Li Y, Gordon D, Morris RJ. Abstract LB-332: Evidence for cutaneous squamous tumors derived from carcinogen-exposed bone marrow. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-lb-332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cytokeratins are frequently found in the blood and bone marrow of patients with epithelial cancers and are attributed to metastasis. We wondered whether we could find keratin expression in blood and bone marrow in untreated adult mice. To address this problem, we have used classical immunoreactivity, Krt1-14;mTmG transgenic mice together with fluorescence activated cell sorting, and quantitative reverse transcriptase polymerase chain reaction. We have made several novel findings. First, we discovered, rare but distinctive, keratin-14 and keratin-15 immunoreactive cells the size of small lymphocytes in blood and bone marrow of untreated mice. Second, using Krt1-14;mTmG transgenic mice, we found low (8.6 GFP positive cells per 10^6 cells analyzed), but significant numbers (p<0.0005) of GFP positive cells in bone marrow of normal adult mice when compared with negative controls. Third, qRT-PCR demonstrated very low but reproducibly detectable expression of keratin-14 mRNA in blood and bone marrow when compared with epidermal keratinocytes: with blood expressing one thousand times, and bone marrow, one hundred thousand times, less than epidermal keratinocytes. Moreover, FACS analysis of fresh bone marrow disclosed a subpopulation of keratin-14 immunoreactive cells that was negative for hematopoietic lineage markers. Furthermore, and even more curious, recipients of bone marrow transplants from DMBA-treated UBC/GFP mice (“toxic bone marrow”) developed GFP-immunoreactive skin tumors upon TPA tumor promotion: four of fifteen mice developed GFP-immunoreactive skin tumors. Of these tumors, four were squamous papillomas, and one was a squamous cell carcinoma. None of the ten control mice receiving normal whole bone marrow developed any skin tumors upon tumor promotion. We conclude from these observations that keratin-14 protein and mRNA are expressed at low, but detectable levels in the blood and bone marrow of mice, and that a subset of “toxic bone marrow” derived cells can be recruited to form epithelial benign and malignant squamous tumors. Building upon these observations should open new avenues of understanding for cutaneous biology, non-melanoma skin cancer, and other epithelia and their cancers.
Citation Format: Sonali Lad, Kelly Johnson, Kelsey Boland, Nyssa Readio, Todd Schuster, Yong Li, Derek Gordon, Rebecca J. Morris. Evidence for cutaneous squamous tumors derived from carcinogen-exposed bone marrow [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-332.
Collapse
Affiliation(s)
| | | | | | | | | | - Yong Li
- 1Hormel Institute, Austin, MN
| | | | | |
Collapse
|
28
|
Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, Fox NL, Groark J, Stohl W, Kleoudis C, Roth D. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Lupus 2018; 27:1489-1498. [PMID: 29807477 PMCID: PMC6066857 DOI: 10.1177/0961203318777634] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Objective To evaluate the safety, tolerability and efficacy of subcutaneous (SC)
belimumab in patients with systemic lupus erythematosus (SLE) beyond 1
year. Methods This was a 24-week, open-label extension following a 52-week, double-blind,
placebo-controlled trial of belimumab SC. Patients who completed the
double-blind phase were eligible to enter the open-label phase. All patients
received weekly belimumab 200 mg SC plus standard SLE therapy. Outcome
measures included safety and efficacy (SLE Response Index (SRI) and SLE
Flare Index (SFI) rates), and changes in biomarker and B cell levels. Results Of 677 patients who completed the 52-week, double-blind phase, 662 entered
the open-label phase; 206 had previously received placebo and 456 had
previously received belimumab. Despite differences in total belimumab
exposure (24 weeks in the placebo-to-belimumab group versus 76 weeks in the
belimumab group), the proportions of patients experiencing more than one
adverse event (AE) or a serious AE in the open-label phase were similar
between groups (placebo-to-belimumab: 51.5 and 6.8%; belimumab: 48.2 and
5.5%, respectively). Most AEs were mild/moderate in severity. Efficacy was
maintained through the extension phase. An SRI response was achieved by
16.1% of patients in the placebo-to-belimumab group and 76.3% patients in
the belimumab group. Furthermore, 1.0% of patients in the
placebo-to-belimumab group and 2.6% of patients in the belimumab group
experienced a severe SFI flare. Conclusion Belimumab SC was well tolerated and efficacy was maintained during the
extension phase of this study. The safety profile of belimumab SC is
consistent with that of previous experience with belimumab. Trial registration ClinicalTrials.gov identifier: NCT01484496
Collapse
Affiliation(s)
- A Doria
- 1 Rheumatology Unit, Department of Medicine, University of Padova, Padua, Italy
| | - D Bass
- 2 GlaxoSmithKline R&D, Philadelphia, PA, USA
| | - A Schwarting
- 3 Division of Rheumatology, University Hospital Mainz, Mainz, Germany.,4 ACURA Rheumazentrum Kliniken, Bad Kreuznach, Germany
| | - A Hammer
- 2 GlaxoSmithKline R&D, Philadelphia, PA, USA
| | - D Gordon
- 2 GlaxoSmithKline R&D, Philadelphia, PA, USA
| | - M Scheinberg
- 5 Centro de Pesquisas Clinicas do Hospital Abreu Sodré, São Paulo, Brazil
| | - N L Fox
- 6 GlaxoSmithKline R&D, Rockville, MD, USA
| | - J Groark
- 2 GlaxoSmithKline R&D, Philadelphia, PA, USA
| | - W Stohl
- 7 Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
| | - C Kleoudis
- 8 Parexel Clinical Research, Raleigh-Durham, NC, USA
| | - D Roth
- 2 GlaxoSmithKline R&D, Philadelphia, PA, USA
| |
Collapse
|
29
|
Sanford J, Super ER, Pinter J, Gordon D, Pierce M, Sage K, Lam D. 0770 Does Obesity Predict Severity of Obstructive Sleep Apnea in Children with Down Syndrome? Sleep 2018. [DOI: 10.1093/sleep/zsy061.769] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- J Sanford
- Oregon Health and Sciences University, Portland, OR
| | - E R Super
- Oregon Health and Sciences University, Portland, OR
| | - J Pinter
- Oregon Health and Sciences University, Portland, OR
| | - D Gordon
- Oregon Health and Sciences University, Portland, OR
| | - M Pierce
- Childrens Minnesota, Minneapolis, MN
| | - K Sage
- Oregon Health and Sciences University, Portland, OR
| | - D Lam
- Oregon Health and Sciences University, Portland, OR
| |
Collapse
|
30
|
|
31
|
Chatham W, Chadha A, Fettiplace J, Kleoudis C, Bass D, Roth D, Gordon D. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus 2017; 26:1483-1490. [PMID: 28467293 PMCID: PMC5673008 DOI: 10.1177/0961203317703495] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Accepted: 03/14/2017] [Indexed: 01/06/2023]
Abstract
Objective Intravenous belimumab 10 mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimumab on immune response to pneumococcal vaccination in patients with systemic lupus erythematosus. Methods This was a Phase 4, open-label study (GSK BEL115470; NCT01597492) conducted in the United States. Patients were randomized (7:9) to receive a 23-valent pneumococcal vaccination four weeks prior to (pre-belimumab cohort) or 24 weeks after (belimumab-concurrent cohort) commencing four-weekly belimumab 10 mg/kg intravenous treatment plus standard systemic lupus erythematosus therapy. Analyses of vaccine titers were performed on the as-treated population (received ≥1 dose of belimumab). The primary endpoint was the proportion of patients with positive antibody responses (≥2-fold increase from pre-vaccination levels, or post-vaccination level ≥ 0.6 µg/mL if pre-vaccination levels were unquantifiable) to ≥1 of 23 pneumococcal vaccine serotypes, four weeks post vaccination. Other endpoints included the proportion of patients with positive antibody responses to ≥2 to ≥10, and ≥11-23 (post hoc analysis) of serotypes. Safety was assessed by monitoring adverse events. Results Seventy-nine patients received pneumococcal vaccination (pre-belimumab cohort, n = 34; belimumab-concurrent cohort, n = 45). The majority (87.3% [69/79]) completed the study; 10 (12.7%) withdrew (patient request, n = 3; adverse event, n = 3; lost to follow-up, n = 2; other, n = 2). At Week 4 post-vaccination, 97.0% (32/33) and 97.6% (40/41) of patients (pre-belimumab and concurrent belimumab cohorts, respectively) had a positive response to ≥1 of 23 pneumococcal serotypes. Over 85% of patients in both cohorts responded to ≥10 of serotypes, approximately 80% responded to ≥12 serotypes, and approximately two-thirds responded to ≥16 serotypes. Little difference was observed between cohorts across a broad response, up to 23 serotypes. Eight (23.5%) patients experienced an adverse event considered by the investigator to be treatment-related in the pre-belimumab cohort and four (8.9%) in the belimumab-concurrent cohort; seven patients experienced non-fatal serious adverse events (pre-belimumab cohort, 11.8% [ n = 4]; concurrent-belimumab cohort, 6.7% [ n = 3]), and no deaths were reported. Conclusion The proportion of patients generating a response to ≥1 pneumococcal serotype did not differ between the pre-belimumab and belimumab-concurrent cohorts; the proportions were also comparable across a broader response (from ≥2 serotypes to 23 serotypes).
Collapse
Affiliation(s)
- W Chatham
- University of Alabama at Birmingham, Birmingham, USA
| | - A Chadha
- Austin Regional Clinic, Austin, USA
| | | | | | | | | | | |
Collapse
|
32
|
Gordon D, Hoh J, Finch SJ, Levenstien MA, Edington J, Li W, Majewski J, Ott J. Two Approaches for Consolidating Results from Genome Scans of Complex Traits: Selection Methods and Scan Statistics. Genet Epidemiol 2017. [DOI: 10.1002/gepi.2001.21.s1.s403] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Derek Gordon
- The Rockefeller University; New York City, New York
| | | | | | | | | | - Wentian Li
- The Rockefeller University; New York City, New York
| | | | - Jürg Ott
- The Rockefeller University; New York City, New York
| |
Collapse
|
33
|
Gordon D, Londono D, Patel P, Kim W, Finch SJ, Heiman GA. An Analytic Solution to the Computation of Power and Sample Size for Genetic Association Studies under a Pleiotropic Mode of Inheritance. Hum Hered 2017; 81:194-209. [PMID: 28315880 DOI: 10.1159/000457135] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Accepted: 01/20/2017] [Indexed: 01/14/2023] Open
Abstract
Our motivation here is to calculate the power of 3 statistical tests used when there are genetic traits that operate under a pleiotropic mode of inheritance and when qualitative phenotypes are defined by use of thresholds for the multiple quantitative phenotypes. Specifically, we formulate a multivariate function that provides the probability that an individual has a vector of specific quantitative trait values conditional on having a risk locus genotype, and we apply thresholds to define qualitative phenotypes (affected, unaffected) and compute penetrances and conditional genotype frequencies based on the multivariate function. We extend the analytic power and minimum-sample-size-necessary (MSSN) formulas for 2 categorical data-based tests (genotype, linear trend test [LTT]) of genetic association to the pleiotropic model. We further compare the MSSN of the genotype test and the LTT with that of a multivariate ANOVA (Pillai). We approximate the MSSN for statistics by linear models using a factorial design and ANOVA. With ANOVA decomposition, we determine which factors most significantly change the power/MSSN for all statistics. Finally, we determine which test statistics have the smallest MSSN. In this work, MSSN calculations are for 2 traits (bivariate distributions) only (for illustrative purposes). We note that the calculations may be extended to address any number of traits. Our key findings are that the genotype test usually has lower MSSN requirements than the LTT. More inclusive thresholds (top/bottom 25% vs. top/bottom 10%) have higher sample size requirements. The Pillai test has a much larger MSSN than both the genotype test and the LTT, as a result of sample selection. With these formulas, researchers can specify how many subjects they must collect to localize genes for pleiotropic phenotypes.
Collapse
Affiliation(s)
- Derek Gordon
- Department of Genetics, The State University of New Jersey, Piscataway, NJ, USA
| | | | | | | | | | | |
Collapse
|
34
|
Flanagan JJ, Rossi AK, Anderoli M, Willard RR, Gordon D, Harling J, Churcher I, Smith I, Zinn N, Bantscheff M, Crews CM, Crew A, Coleman KG, Winkler JD, Qian Y. Abstract S4-03: Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-s4-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
ERα-positive breast cancers comprise approximately 80% of all newly diagnosed cases. Current treatment approaches targeting ER signaling include antagonizing and/or downregulating ER or reducing estrogen levels. Faslodex (fulvestrant) is the only clinically-approved agent that is both a potent ER antagonist and downregulator but has limitations given its pharmacokinetics and route of administration. Over the past several years, targeted ER therapies have focused on developing selective estrogen receptor downregulators (SERDs, i.e, GDC-0810, GDC-0927, AZD9496, RAD1901). The mechanisms involved in ER downregulation by SERD binding are not completely understood, but evidence suggests that conformational changes in the receptor upon ligand binding combined with specific co-regulator interactions destabilize the receptor making it a target for passive proteasomal degradation. We hypothesized that the complex ER pharmacology required for SERD-based passive degradation might be different across various ER-positive cell lines and that targeted degradation of the receptor by actively recruiting the ubiquitin-proteasome machinery would provide a better approach for reducing ER levels. To test this hypothesis, we developed potent molecules directed against ER using our pioneering technology—proteolysis targeting chimeras (PROTACs). PROTACs are heterobifunctional molecules that actively recruit specific E3 ligases resulting in ubiquitylation and degradation of target proteins. When testing for ER degradation using several SERDs and ER PROTACs, we discovered that both fulvestrant and ER PROTACs provided robust degradation in all ER-positive lines (<1 nM 50% degradation; >90% reduction) whereas other SERDs did not degrade or only modestly degraded the receptor. Importantly, MCF-7 cells were uniquely sensitive to SERD-based degradation of ER compared to other cell lines. Subcutaneous administration of fulvestrant (1mpk) or ER PROTACs (10 mpk) reduced uterine ER alpha levels in immature rats (>65% reduction). PROTAC-mediated degradation of ER was also achieved in breast cancer xenografts. To further validate the PROTAC mechanism, incubation of ER-positive cells with ER PROTACs resulted in increased levels of poly-ubiquitylated ERα when compared to SERDs. Lastly, to demonstrate the specificity of PROTAC-mediated ERα degradation, we utilized a cellular expression proteomics-based approach to examine over 7,000 proteins. In this experiment, only ERα and several known proteins whose genes are regulated by ERα, were significantly reduced by PROTACs. It remains to be seen how the current class of investigational downregulators will perform in the clinic. More importantly, a better understanding of the therapeutic potential and benefit of degrading the receptor instead of inhibiting the receptor needs to be explored. To that end, we continue to develop and characterize novel ER PROTACs with the anticipation that targeted ERα degradation will provide a greater clinical benefit than receptor antagonism.
Citation Format: Flanagan JJ, Rossi AK, Anderoli M, Willard RR, Gordon D, Harling J, Churcher I, Smith I, Zinn N, Bantscheff M, Crews CM, Crew A, Coleman KG, Winkler JD, Qian Y. Targeted and selective degradation of estrogen receptor (ER) alpha by PROTACs [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr S4-03.
Collapse
Affiliation(s)
- JJ Flanagan
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - AK Rossi
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - M Anderoli
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - RR Willard
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - D Gordon
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - J Harling
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - I Churcher
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - I Smith
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - N Zinn
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - M Bantscheff
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - CM Crews
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - A Crew
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - KG Coleman
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - JD Winkler
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| | - Y Qian
- Arvinas LLC, New Haven, CT; GSK Medicines Research Centre, Stevenage, United Kingdom; Yale University, New Haven, CT
| |
Collapse
|
35
|
Stover Fiscalini A, Theiner S, Kaplan C, Sarrafan S, Sawyer S, Liang A, Rosenberg-Wohl S, Gordon D, Frick M, Borowsky A, Anton-Culver H, Naeim A, LaCroix A, Cink T, Esserman L, van 't Veer L. Abstract P5-02-03: Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-02-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The WISDOM Study (Women Informed to Screen Depending on Measures of risk) aims to examine the effectiveness of personalized breast cancer screening and to bring objective recommendations to the current mammography screening debate. The WISDOM Study is a 100,000 woman randomized trial with a preference-tolerant design that will determine if risk-based screening (RBS) vs. annual screening, is as safe, less morbid, enables prevention and is preferred by women. A pilot was conducted to test the logistics of online participation and examine the acceptance of the study design and approach.
Methods: Women were recruited from the UCSF site of the Athena Breast Health Network, a clinical care-research cohort of 110,000 women from the 5 University of California Medical Centers and Sanford Health. The pilot recruited women via email who were 40 -74 years of age with no history of breast cancer and a normal mammogram in the past year. Those interested visited the WISDOM Study website (wisdomstudy.org), signed up, elected randomization or self-selection, provided electronic consent using DocuSign (eConsent), and completed genetic testing (RBS arm). The Breast Cancer Surveillance Consortium (BCSC) model (standard risk factors, ethnicity, and breast density) in addition to genetic testing (9 genes and 75 SNPs) was used to calculate breast cancer risks that informed the start and frequency of screening for women in the RBS arm. BCSC was also used in the annual screening arm but did not inform mammography screening recommendations. The pilot used a mixed method approach (using enrollment data, Exit Survey data, individual interviews and focus groups) to assess enrollment preferences, randomization acceptance and overall study workflow.
Results: The online electronic enrollment process and patient engagement portal was successfully implemented. In total, 639 women were invited, 235 registered (34%), and 171 (27%) consented to the pilot. Of these, 74% (127) elected to be randomized, and 26% chose to self-assign (66% chose annual screening (29)). Mean age was 56 years and the ethnic breakdown of the cohort was: 79% White, 10% Asian, 7% Latino, 3% Black, 1% other. 92% of those in the risk-based arm of the study completed genetic testing and were given results; only one genetic mutation was identified and occurred in CHEK2. Within the RBS arm (78), mammography recommendations were: 61% no further mammography until the age of 50, 22% biennial, 11% annual, and 6% every 6 month alternating MRI and mammogram. Exit Survey data illuminated confusion in study arm names (risk-based vs. annual), randomization acceptance (74%), annual arm preference in the self-selection group (66%), eConsent satisfaction (90%), enrollment process ease of use (88%), and website content, navigation and appearance satisfaction (66%). The pilot concluded in May 2016 to allow for refinements prior to the full trial.
Conclusion: Our pilot demonstrates that the majority of women are willing to be randomized and participate in an online screening study to answer the important question on optimal breast cancer screening. The pilot study results will inform implementation of the 100,000 women WISDOM Study which launches in fall of 2016.
Citation Format: Stover Fiscalini A, Theiner S, Kaplan C, Sarrafan S, Sawyer S, Liang A, Rosenberg-Wohl S, Gordon D, Frick M, Borowsky A, Anton-Culver H, Naeim A, LaCroix A, Cink T, Collaboration Athena Breast Health Network and Advocate Partners, Esserman L, van 't Veer L. Evaluating the feasibility of a web-based preference-tolerant randomized trial of risk-based vs. annual breast cancer screening: WISDOM study pilot [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-02-03.
Collapse
Affiliation(s)
- A Stover Fiscalini
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - S Theiner
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - C Kaplan
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - S Sarrafan
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - S Sawyer
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - A Liang
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - S Rosenberg-Wohl
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - D Gordon
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - M Frick
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - A Borowsky
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - H Anton-Culver
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - A Naeim
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - A LaCroix
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - T Cink
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - L Esserman
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | - L van 't Veer
- University of California, San Francisco, San Francisco, CA; University of California, Davis, Sacramento, CA; University of California, Irvine, Irvine, CA; University of California, Los Angeles, Los Angeles, CA; University of California, San Diego, San Diego, CA; Sanford Health, Sioux Falls, SD
| | | |
Collapse
|
36
|
Sawair F, Hassona Y, Irwin C, Stephenson M, Hamilton P, Maxwell P, Gordon D, Leonard A, Napier S. p53, Cyclin D1, p21 (WAF1) and Ki-67 (MIB1) Expression at Invasive Tumour Fronts of Oral Squamous Cell Carcinomas and Development of Local Recurrence. Asian Pac J Cancer Prev 2017; 17:1243-9. [PMID: 27039754 DOI: 10.7314/apjcp.2016.17.3.1243] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Expression of p53, cyclin D1, p21 (WAF1) and Ki-67 (MIB1) was evaluated in oral squamous cell carcinoma (OSCC) to test whether levels of these markers at invasive tumour fronts (ITFs) could predict the development of local recurrence. MATERIALS AND METHODS Archived paraffin-embedded specimens from 51 patients with T1/T2 tumours were stained immunohistochemically and analysed quantitatively. Local recurrence-free survival was tested with Kaplan-Meier survival plots (log-rank test) using median values to define low and high expression groups and with a Cox's proportional hazards model in which the expression scores were entered as continuous variables. RESULTS The assessment of expression of all markers was highly reliable, univariate analysis showing that patients with clear surgical margins, with low cyclin D1 and high p21 expression at the ITF had the best local recurrence-free survival. Multivariate analysis showed that these three parameters were independent prognostic factors but that neither p53 nor MIB1 expression were of prognostic value. CONCLUSIONS Assessment of p53, cyclin D1, p21 (WAF1), and Ki-67 (MIB1) at the ITF could help to predict local recurrence in early stage oral squamous cell carcinoma cases.
Collapse
Affiliation(s)
- F Sawair
- Faculty of Dentistry, The University of Jordan, Amman, Jordan E-mail :
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Bale SD, Goetz K, Harvey PR, Turin P, Bonnell JW, de Wit TD, Ergun RE, MacDowall RJ, Pulupa M, Andre M, Bolton M, Bougeret JL, Bowen TA, Burgess D, Cattell CA, Chandran BDG, Chaston CC, Chen CHK, Choi MK, Connerney JE, Cranmer S, Diaz-Aguado M, Donakowski W, Drake JF, Farrell WM, Fergeau P, Fermin J, Fischer J, Fox N, Glaser D, Goldstein M, Gordon D, Hanson E, Harris SE, Hayes LM, Hinze JJ, Hollweg JV, Horbury TS, Howard RA, Hoxie V, Jannet G, Karlsson M, Kasper JC, Kellogg PJ, Kien M, Klimchuk JA, Krasnoselskikh VV, Krucker S, Lynch JJ, Maksimovic M, Malaspina DM, Marker S, Martin P, Martinez-Oliveros J, McCauley J, McComas DJ, McDonald T, Meyer-Vernet N, Moncuquet M, Monson SJ, Mozer FS, Murphy SD, Odom J, Oliverson R, Olson J, Parker EN, Pankow D, Phan T, Quataert E, Quinn T, Ruplin SW, Salem C, Seitz D, Sheppard DA, Siy A, Stevens K, Summers D, Szabo A, Timofeeva M, Vaivads A, Velli M, Yehle A, Werthimer D, Wygant JR. The FIELDS Instrument Suite for Solar Probe Plus: Measuring the Coronal Plasma and Magnetic Field, Plasma Waves and Turbulence, and Radio Signatures of Solar Transients. Space Sci Rev 2016; 204:49-82. [PMID: 29755144 PMCID: PMC5942226 DOI: 10.1007/s11214-016-0244-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
NASA's Solar Probe Plus (SPP) mission will make the first in situ measurements of the solar corona and the birthplace of the solar wind. The FIELDS instrument suite on SPP will make direct measurements of electric and magnetic fields, the properties of in situ plasma waves, electron density and temperature profiles, and interplanetary radio emissions, amongst other things. Here, we describe the scientific objectives targeted by the SPP/FIELDS instrument, the instrument design itself, and the instrument concept of operations and planned data products.
Collapse
Affiliation(s)
- S D Bale
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
- Physics Department, University of California, Berkeley, CA, USA
| | - K Goetz
- School of Physics and Astronomy, University of Minnesota, Minneapolis, MN, USA
| | - P R Harvey
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - P Turin
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - J W Bonnell
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - T Dudok de Wit
- LPC2E, CNRS, 3A avenue de la Recherche Scientifique, Orléans, France
| | - R E Ergun
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO, USA
| | - R J MacDowall
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - M Pulupa
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - M Andre
- Swedish Institute of Space Physics (IRF), Uppsala, Sweden
| | - M Bolton
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO, USA
| | | | - T A Bowen
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
- Physics Department, University of California, Berkeley, CA, USA
| | - D Burgess
- Astronomy Unit, Queen Mary, University of London, London, UK
| | - C A Cattell
- School of Physics and Astronomy, University of Minnesota, Minneapolis, MN, USA
| | - B D G Chandran
- Department of Physics, University of New Hampshire, Durham, NH, USA
| | - C C Chaston
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - C H K Chen
- Department of Physics, Imperial College, London, UK
| | - M K Choi
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - J E Connerney
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - S Cranmer
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO, USA
| | - M Diaz-Aguado
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - W Donakowski
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - J F Drake
- Department of Physics, University of Maryland, College Park, MD, USA
| | - W M Farrell
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - P Fergeau
- LPC2E, CNRS, 3A avenue de la Recherche Scientifique, Orléans, France
| | - J Fermin
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - J Fischer
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - N Fox
- Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USA
| | - D Glaser
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - M Goldstein
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - D Gordon
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - E Hanson
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
- Physics Department, University of California, Berkeley, CA, USA
| | - S E Harris
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - L M Hayes
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - J J Hinze
- School of Physics and Astronomy, University of Minnesota, Minneapolis, MN, USA
| | - J V Hollweg
- Department of Physics, University of New Hampshire, Durham, NH, USA
| | - T S Horbury
- Department of Physics, Imperial College, London, UK
| | - R A Howard
- Space Science Division, Naval Research Laboratory, Washington, DC, USA
| | - V Hoxie
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO, USA
| | - G Jannet
- LPC2E, CNRS, 3A avenue de la Recherche Scientifique, Orléans, France
| | - M Karlsson
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO, USA
| | - J C Kasper
- University of Michigan, Ann Arbor, MI, USA
| | - P J Kellogg
- School of Physics and Astronomy, University of Minnesota, Minneapolis, MN, USA
| | - M Kien
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO, USA
| | - J A Klimchuk
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | | | - S Krucker
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - J J Lynch
- School of Physics and Astronomy, University of Minnesota, Minneapolis, MN, USA
| | | | - D M Malaspina
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO, USA
| | - S Marker
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - P Martin
- LPC2E, CNRS, 3A avenue de la Recherche Scientifique, Orléans, France
| | | | - J McCauley
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - D J McComas
- Southwest Research Institute, San Antonio, TX, USA
| | - T McDonald
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | | | - M Moncuquet
- LESIA, Observatoire de Paris, Meudon, France
| | - S J Monson
- School of Physics and Astronomy, University of Minnesota, Minneapolis, MN, USA
| | - F S Mozer
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - S D Murphy
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - J Odom
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - R Oliverson
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - J Olson
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - E N Parker
- Department of Astronomy and Astrophysics, University of Chicago, Chicago, IL, USA
| | - D Pankow
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - T Phan
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - E Quataert
- Astronomy Department, University of California, Berkeley, CA, USA
| | - T Quinn
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | | | - C Salem
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - D Seitz
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - D A Sheppard
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - A Siy
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - K Stevens
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO, USA
| | - D Summers
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO, USA
| | - A Szabo
- NASA Goddard Space Flight Center, Greenbelt, MD, USA
| | - M Timofeeva
- LPC2E, CNRS, 3A avenue de la Recherche Scientifique, Orléans, France
| | - A Vaivads
- Swedish Institute of Space Physics (IRF), Uppsala, Sweden
| | - M Velli
- Earth, Planetary, and Space Sciences, UCLA, Los Angelos, CA, USA
| | - A Yehle
- Laboratory for Atmospheric and Space Physics, University of Colorado, Boulder, CO, USA
| | - D Werthimer
- Space Sciences Laboratory, University of California, Berkeley, CA, USA
| | - J R Wygant
- School of Physics and Astronomy, University of Minnesota, Minneapolis, MN, USA
| |
Collapse
|
38
|
Ayoola A, Sukumaran S, Kumar R, Gordon D, Roy A, Vantandoust S, Koczwara B, Kichenadasse G, Karapetis C. Efficacy of influenza vaccine (FluVax) in patients on chemotherapy (POCT): final data analysis from South Australia. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw390.54] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Hewagama S, Spelman T, Woolley M, McLeod J, Gordon D, Einsiedel L. The Epidemiology of Staphylococcus aureus and Panton-Valentine Leucocidin (pvl) in Central Australia, 2006-2010. BMC Infect Dis 2016; 16:382. [PMID: 27502499 PMCID: PMC4977826 DOI: 10.1186/s12879-016-1698-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Accepted: 07/08/2016] [Indexed: 11/21/2022] Open
Abstract
Background The Central Australian Indigenous population has a high incidence of Staphylococcus aureus bacteremia (SAB) but little is known about the local molecular epidemiology. Methods Prospective observational study of bacteremic and nasal colonizing S.aureus isolates between June 2006 to June 2010. All isolates underwent single nucleotide polymorphism (SNP) genotyping and testing for the presence of the Panton-Valentine Leucocidin (pvl) gene. Results Invasive isolates (n = 97) were predominantly ST93 (26.6 %) and pvl positive (54.3 %), which was associated with skin and soft tissue infections (OR 4.35, 95 % CI 1.16, 16.31). Non-multiresistant MRSA accounted for 31.9 % of bacteremic samples and showed a trend to being healthcare associated (OR 2.16, 95 % CI 0.86, 5.40). Non-invasive isolates (n = 54) were rarely ST93 (1.9 %) or pvl positive (7.4 %). Conclusions In Central Australia, ST93 was the dominant S.aureus clone, and was frequently pvl positive and associated with an aggressive clinical phenotype. Whether non-nasal carriage is more important with invasive clones or whether colonization occurs only transiently remains to be elucidated.
Collapse
Affiliation(s)
- S Hewagama
- Alice Springs Hospital, Alice Springs, NT, Australia.
| | - T Spelman
- Flinders University/Northern Territory Rural Clinical School, Alice Springs, NT, Australia
| | | | - J McLeod
- Alice Springs Hospital, Alice Springs, NT, Australia.,NT Pathology, Alice Springs, NT, Australia
| | - D Gordon
- SA Pathology, Adelaide, Australia
| | - L Einsiedel
- Alice Springs Hospital, Alice Springs, NT, Australia.,Flinders University/Northern Territory Rural Clinical School, Alice Springs, NT, Australia.,Baker IDI Heart and Diabetes Institute, Alice Springs, NT, Australia
| |
Collapse
|
40
|
Sheikh S, Fox N, Hammer A, Struemper H, Groark J, Roth D, Gordon D. THU0305 Pharmacokinetics of Switching from Intravenous To Subcutaneous Belimumab for Patients with Systemic Lupus Erythematosus (SLE). Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4162] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
41
|
Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer A, Groark J, Bass D, Fox N, Roth D, Gordon D. LB0001 Efficacy and Safety of Subcutaneous Belimumab plus Standard Care in Patients with Systemic Lupus Erythematosus (SLE) with Low Complement and Positive Anti-DSDNA:. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.6236] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
42
|
Sheikh S, Fox N, Hammer A, Struemper H, Groark J, Roth D, Gordon D. AB0416 Reliability and Safety of A Novel Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus (SLE):. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.4194] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Yapa SWS, Roth D, Gordon D, Struemper H. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program. Lupus 2016; 25:1448-1455. [PMID: 27072354 PMCID: PMC5054300 DOI: 10.1177/0961203316642309] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Background Belimumab is a recombinant, human, IgG1λ monoclonal antibody that targets B-lymphocyte stimulator. The intravenous formulation is indicated for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Belimumab has been formulated for subcutaneous (SC) administration to improve patient convenience. This post-hoc modeling and simulation analysis characterizes the population pharmacokinetics (PK) of SC belimumab, and compares the exposure profiles of the approved belimumab IV dose-10 mg/kg every four weeks-to the 200 mg SC weekly dose in SLE patients, highlighting key pharmacological differences relevant for clinicians. Methods Data from two Phase 1 studies in US American and Japanese healthy subjects were analyzed with a non-linear mixed effects modeling approach. The resulting SC population PK model and a previously developed IV population PK model were used to conduct simulation trials in a Phase 3 IV belimumab SLE patient population, comparing chronic exposure profiles and exposure ranges stratified by body weight tertiles for IV vs SC dosing. Results The PK of belimumab following SC administration was best described by a linear two-comment model. The estimates for clearance, steady-state volume of distribution, and bioavailability were 208 mL/day, 5250 mL, and 76%, respectively. After four weeks of SC dosing, simulated belimumab concentrations exceeded the steady-state trough concentrations of the IV dosing regimen. At steady state simulated serum profiles demonstrated comparable average belimumab concentrations (Cavg,ss) after IV and SC dosing. Simulated belimumab exposures demonstrated largely overlapping concentration ranges following 200 mg SC weekly and 10 mg/kg IV every four weeks dosing. Discussion The predicted Cavg,ss of belimumab in SLE patients was comparable following 200 mg SC weekly and 10 mg/kg IV every four weeks dosing. The simulated belimumab accumulation following SC weekly dosing indicated that administration of a loading dose was not required. Similar Cavg,ss ranges were predicted for fixed dose SC and weight-proportional IV regimens in the simulated SLE population, albeit with a reversed body-size-to-exposure relationship for the SC regimen. These findings provide rheumatologists with a better understanding of expected differences in belimumab exposure when comparing IV and SC dosing regimens.
Collapse
Affiliation(s)
| | - D Roth
- 2 GlaxoSmithKline, Collegeville, USA
| | - D Gordon
- 2 GlaxoSmithKline, Collegeville, USA
| | | |
Collapse
|
44
|
Morris R, Gordon D, Li Y, Readio N, Johnson K, Boland K, Lad S. 669 Evidence for expression of epidermal keratin and mRNA in blood and bone marrow of adult mice. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.02.711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
45
|
Dagal A, Lesnik I, Bentov N, Dong J, Qiu Q, Hayes K, Gordon D. (458) Using a perioperative enhanced recovery care pathway for major spine surgery (PERMS) to improve pain management & patient-reported outcomes. The Journal of Pain 2016. [DOI: 10.1016/j.jpain.2016.01.435] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
46
|
Bruce IN, Urowitz M, van Vollenhoven R, Aranow C, Fettiplace J, Oldham M, Wilson B, Molta C, Roth D, Gordon D. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus 2016; 25:699-709. [PMID: 26936891 PMCID: PMC4958991 DOI: 10.1177/0961203315625119] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2015] [Accepted: 12/01/2015] [Indexed: 01/31/2023]
Abstract
Objective To examine long-term organ damage and safety following treatment with belimumab plus standard of care (SoC) in patients with systemic lupus erythematosus (SLE). Methods Pooled data were examined from two ongoing open-label studies that enrolled patients who completed BLISS-52 or BLISS-76. Patients received belimumab every four weeks plus SoC. SLICC Damage Index (SDI) values were assessed every 48 weeks (study years) following belimumab initiation (baseline). The primary endpoint was change in SDI from baseline at study years 5–6. Incidences of adverse events (AEs) were reported for the entire study period. Results The modified intent-to-treat (MITT) population comprised 998 patients. At baseline, 940 (94.2%) were female, mean (SD) age was 38.7 (11.49) years, and disease duration was 6.7 (6.24) years. The mean (SD) SELENA-SLEDAI and SDI scores were 8.2 (4.18) and 0.7 (1.19), respectively; 411 (41.2%) patients had organ damage (SDI = 1: 235 (23.5%); SDI ≥ 2: 176 (17.6%)) prior to belimumab. A total of 427 (42.8%) patients withdrew overall; the most common reasons were patient request (16.8%) and AEs (8.5%). The mean (SD) change in SDI was +0.2 (0.48) at study years 5–6 (n = 403); 343 (85.1%) patients had no change from baseline in SDI score (SDI +1: 46 (11.4%), SDI +2: 13 (3.2%), SDI +3: 1 (0.2%)). Of patients without organ damage at baseline, 211/241 (87.6%) had no change in SDI and the mean change (SD) in SDI was +0.2 (0.44). Of patients with organ damage at baseline, 132/162 (81.5%) had no change in SDI and the mean (SD) change in SDI was +0.2 (0.53). The probability of not having a worsening in SDI score was 0.88 (95% CI: 0.85, 0.91) and 0.75 (0.67, 0.81) in those without and with baseline damage, respectively (post hoc analysis). Drug-related AEs were reported for 433 (43.4%) patients; infections/infestations (282, 28.3%) and gastrointestinal disorders (139, 13.9%) were the most common. Conclusion Patients with SLE treated with long-term belimumab plus SoC had a low incidence of organ damage accrual and no unexpected AEs. High-risk patients with pre-existing organ damage also had low accrual, suggesting a favorable effect on future damage development.
Collapse
Affiliation(s)
- I N Bruce
- Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute for Inflammation and Repair, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, UK The Kellgren Centre for Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - M Urowitz
- University of Toronto and Toronto Western Hospital, Toronto, ON, Canada
| | | | - C Aranow
- The Feinstein Institute for Medical Research, Manhasset, NY, USA
| | | | - M Oldham
- GSK, Stevenage, Hertfordshire, UK
| | - B Wilson
- GSK, Research Triangle Park, NC, USA
| | | | - D Roth
- GSK, Philadelphia, PA, USA
| | | |
Collapse
|
47
|
Schoenian S, O'Brien D, Semler J, Gordon D, Bennett MB. 106 Carcass and fatty acid profile of pen-fed and pasture-raised meat goat kids. J Anim Sci 2016. [DOI: 10.2527/ssasas2015-106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab. Lupus 2015; 25:346-54. [PMID: 26385220 PMCID: PMC4785993 DOI: 10.1177/0961203315604909] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Accepted: 08/18/2015] [Indexed: 11/25/2022]
Abstract
Introduction Patients with systemic lupus erythematosus (SLE) with B-lymphocyte stimulator (BLyS) levels ≥ 2 ng/mL are at increased risk of flare. A regression analysis was undertaken to identify routine clinical measures that correlate with BLyS ≥ 2 ng/mL. Efficacy and safety of belimumab 10 mg/kg were examined in patients with BLyS ≥ 2 ng/mL and < 2 ng/mL. Methods Data from BLISS-52 and -76 (N = 1684) were pooled post hoc. A univariate logistic regression was employed to identify factors predictive of baseline BLyS ≥ 2 ng/mL. Factors significant at the 0.05 level then entered a stepwise logistic regression as covariates. Efficacy endpoints included SLE responder index (SRI), ≥ 4-point reduction in Safety of Estrogens in Lupus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) and risk of severe flare over 52 weeks. Adverse events (AEs) were analyzed for each treatment arm and BLyS subgroup. Results Baseline predictors of BLyS ≥ 2 ng/mL included positive anti-Smith (≥ 15 U/mL), low complement (C) 3 (< 900 mg/L), anti-double-stranded DNA (anti-dsDNA) 80–200 and ≥ 200 IU/mL, immunosuppressant usage, proteinuria, elevated C-reactive protein (CRP), and low total lymphocyte count for all patients. Belimumab 10 mg/kg led to significantly greater SRI responses over 52 weeks versus placebo in both BLyS subgroups, though treatment differences were numerically greater at Week 52 in the BLyS ≥ 2 ng/mL group (24.1%, p < 0.0001) compared with BLyS < 2 ng/mL (8.2%, p = 0.0158). Results were similar for ≥ 4-point reduction in SELENA-SLEDAI. Risk of severe flare over 52 weeks was significantly reduced with belimumab 10 mg/kg versus placebo in the BLyS ≥ 2 ng/mL group (p = 0.0002). AEs were similar across treatment arms and BLyS subgroups. Conclusions Positive anti-Smith, low C3, anti-dsDNA ≥ 80 IU/mL, immunosuppressant usage, proteinuria, elevated CRP, and low total lymphocyte count were predictors of BLyS ≥ 2 ng/mL. Monitoring these factors could identify patients with BLyS ≥ 2 ng/mL who are at risk of flare.
Collapse
Affiliation(s)
- D A Roth
- Research and Development, GlaxoSmithKline, Philadelphia, PA, USA
| | - A Thompson
- Research and Development, GlaxoSmithKline, Research Triangle Park, NC, USA
| | - Y Tang
- Research and Development, GlaxoSmithKline, Research Triangle Park, NC, USA
| | - A E Hammer
- Research and Development, GlaxoSmithKline, Research Triangle Park, NC, USA
| | - C T Molta
- Research and Development, GlaxoSmithKline, Philadelphia, PA, USA
| | - D Gordon
- Research and Development, GlaxoSmithKline, Philadelphia, PA, USA
| |
Collapse
|
49
|
Abdalrahaman N, McComb C, Foster JE, McLean J, Lindsay RS, McClure J, McMillan M, Drummond R, Gordon D, McKay GA, Shaikh MG, Perry CG, Ahmed SF. Deficits in Trabecular Bone Microarchitecture in Young Women With Type 1 Diabetes Mellitus. J Bone Miner Res 2015; 30:1386-93. [PMID: 25627460 DOI: 10.1002/jbmr.2465] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2014] [Revised: 01/20/2015] [Accepted: 01/21/2015] [Indexed: 01/27/2023]
Abstract
The pathophysiological mechanism of increased fractures in young adults with type 1 diabetes mellitus (T1DM) is unclear. We conducted a case-control study of trabecular bone microarchitecture and vertebral marrow adiposity in young women with T1DM. Thirty women with T1DM with a median age (range) age of 22.0 years (16.9, 36.1) attending one outpatient clinic with a median age at diagnosis of 9.7 years (0.46, 14.8) were compared with 28 age-matched healthy women who acted as controls. Measurements included MRI-based assessment of proximal tibial bone volume/total volume (appBV/TV), trabecular separation (appTb.Sp), vertebral bone marrow adiposity (BMA), and abdominal adipose tissue and biochemical markers of GH/IGF-1 axis (IGF-1, IGFBP3, ALS) and bone turnover. Median appBV/TV in cases and controls was 0.3 (0.22, 0.37) and 0.33 (0.26, 0.4), respectively (p = 0.018) and median appTb.Sp in T1DM was 2.59 (2.24, 3.38) and 2.32 (2.03, 2.97), respectively (p = 0.012). The median appBV/TV was 0.28 (0.22, 0.33) in those cases with retinopathy (n = 15) compared with 0.33 (0.25, 0.37) in those without retinopathy (p = 0.02). Although median visceral adipose tissue in cases was higher than in controls at 5733 mm(3) (2030, 11,144) and 3460 mm(3) (1808, 6832), respectively (p = 0.012), there was no difference in median BMA, which was 31.1% (9.9, 59.9) and 26.3% (8.5, 49.8) in cases and controls, respectively (p = 0.2). Serum IGF-1 and ALS were also lower in cases, and the latter showed an inverse association to appTbSp (r = -0.30, p = 0.04). Detailed MRI studies in young women with childhood-onset T1DM have shown clear deficits in trabecular microarchitecture of the tibia. Underlying pathophysiological mechanisms may include a microvasculopathy.
Collapse
Affiliation(s)
- Naiemh Abdalrahaman
- Developmental Endocrinology Research Group, School of Medicine, University of Glasgow, Glasgow, UK
| | - Christie McComb
- Clinical Physics, NHS Greater Glasgow & Clyde, Glasgow, UK.,BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
| | - John E Foster
- Clinical Physics, NHS Greater Glasgow & Clyde, Glasgow, UK.,BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
| | - John McLean
- Clinical Physics, NHS Greater Glasgow & Clyde, Glasgow, UK.,Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
| | - Robert S Lindsay
- BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.,Stobhill Diabetes Centre, Stobhill Hospital, Glasgow, UK
| | - John McClure
- BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
| | - Martin McMillan
- Developmental Endocrinology Research Group, School of Medicine, University of Glasgow, Glasgow, UK
| | | | - Derek Gordon
- Stobhill Diabetes Centre, Stobhill Hospital, Glasgow, UK
| | - Gerard A McKay
- Stobhill Diabetes Centre, Stobhill Hospital, Glasgow, UK
| | - M Guftar Shaikh
- Developmental Endocrinology Research Group, School of Medicine, University of Glasgow, Glasgow, UK
| | - Colin G Perry
- Stobhill Diabetes Centre, Stobhill Hospital, Glasgow, UK
| | - S Faisal Ahmed
- Developmental Endocrinology Research Group, School of Medicine, University of Glasgow, Glasgow, UK
| |
Collapse
|
50
|
Biswas A, Echt M, Altschul D, Gordon D. E-120 novel double catheter technique with detachable microcatheter for treatment of arteriovenous malformations. J Neurointerv Surg 2015. [DOI: 10.1136/neurintsurg-2015-011917.195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|